Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study in individuals with mild to moderate Alzheimer's Disease is designed to assess:(1)
safety and tolerability (2) the capacity of subcutaneous bapineuzumab to reduce brain amyloid
load as measured by positron emission tomography (PET) scans.
Phase:
Phase 2
Details
Lead Sponsor:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC